Introduction

61
Despite improvements in patient management, infection control policies, early detection and 62 eradication therapies that have increased the mean life expectancy of cystic fibrosis (CF) patients 63 to about 37 years, most of these patients eventually succumb to chronic pulmonary bacterial 64 infections [1] [2] [3] [4] . The most prominent pathogen in CF patients, the gram-negative bacterium 65 Pseudomonas aeruginosa, is becoming increasingly resistant to antibiotics [5] , leading to a 66 gradual decrease in the clinical benefits of antibiotic treatment over time.
68
In the environment, microbial communities are controlled by various mechanisms, including the 69 antagonistic action of their specific viruses, through the combined activity of temperate and 70 virulent bacteriophages [6] [7] [8] [9] [10] . Bacteriophages were used in medicine (phage therapy), back in 71 early 20th century, before the discovery of the first antibiotics [11, 12] . With the current alarming 72 increase in the frequency of infections caused by antibiotic-resistant pathogens and the lack of 73 new antibiotics, phage therapy is returning to the spotlight. Recent support from experimental 74 data and experience accumulated over 80 years in this field in some European countries (Georgia, 75 Russia, Poland) are in favour of the use of virulent bacteriophages for treating lung infections 76 [13] [14] [15] [16] [17] [18] [19] [20] . As a further step towards applications of bacteriophages in human medicine, we 77 evaluated their potential to infect bacteria in the challenging environment of the lungs, by 78 performing an ex vivo study on sputum samples from 58 chronically infected CF patients. 
Methods
82
Study design 83 We carried out a multicentre cross-sectional study on sputum samples from 58 CF patients 84 recruited from CF centres in Montpellier (n=23), Nancy (n=20) and the Necker Hospital in Paris 85 (n=15). This study was approved by the regional ethics committee (Nimes, registered under 86 number 2011-A01197-34) and declared to ClinicalTrial.gov (no. NCT01818206).
88
Bacteria and bacteriophage strains 89 We used the P. aeruginosa PAK strain to amplify bacteriophages PAK_P1, PAK_P2, PAK_P3, (PAK, CHA, PAO1, Aa245) were cultured at 37°C in LB medium, with shaking, and 94 bacteriophage lysates were prepared and purified as described elsewhere [20] . The cocktail of 95 these 10 bacteriophages was freshly prepared from bacteriophage solutions, each of which had 96 been titrated on the corresponding host the day before sample processing and on the day of 97 processing. Bacteriophage titration was performed by serial dilutions spotted in triplicate on 98 bacterial lawns. This cocktail was assembled from bacteriophages available in our laboratory 99 without any prior knowledge on their efficacy on a large collection of CF P. aeruginosa strains.
100
New bacteriophages infecting colony #4 from sputum sample 04 were isolated as described 
Sputum sample processing
104
Four aliquots of sputum samples were used to evaluate the count of bacteria and bacteriophages 105 before and after addition of the bacteriophages cocktail during 6 h (see Figure 1 and supplemental 106 methods). Bacteria were selected on cetrimide agar and bacteriophages counts were obtained 107 using the 4 indicative strains.
108
The reproducibility and accuracy of our counting procedure leading to the definition of threshold 109 values are described in details in the supplemental methods. 
Results
157
Characteristics of the patients and treatment of the samples
158
The characteristics of the 58 CF patients enrolled in this study are reported in Table 1 . Each of 159 the 58 sputum samples collected was split into four aliquots. We added a cocktail of ten 160 bacteriophages infecting P. aeruginosa to one of these aliquots and buffer alone to a second 161 aliquot; the other two aliquots were used for subsequent analysis (figure 1; methods bacteriophage sensitivity [24, 25] . In group C samples, the decrease in the bacteriophage- active bacteriophage, PAK_P5, is genetically closely related to PAK_P3, P3_CHA and CHA_P1
274
(the least active of the ten bacteriophages tested). 
